Compare · AZN vs SPRO
AZN vs SPRO
Side-by-side comparison of AstraZeneca PLC (AZN) and Spero Therapeutics Inc. (SPRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and SPRO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $262.80B, about 2082.0x SPRO ($126.2M).
- Over the past year, AZN is down 9.9% and SPRO is down 17.6% - AZN leads by 7.7 points.
- AZN has been more active in the news (14 items in the past 4 weeks vs 12 for SPRO).
- AZN has more recent analyst coverage (25 ratings vs 3 for SPRO).
- Company
- AstraZeneca PLC
- Spero Therapeutics Inc.
- Price
- $169.63-1.15%
- $2.18+3.81%
- Market cap
- $262.80B
- $126.2M
- 1M return
- -5.13%
- -13.83%
- 1Y return
- -9.91%
- -17.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2017
- News (4w)
- 14
- 12
- Recent ratings
- 25
- 3
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Spero Therapeutics Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts.
Latest AZN
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest SPRO
- Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
- Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
- Director Deshpande Milind was granted 10,000 shares, increasing direct ownership by 11% to 101,454 units (SEC Form 4)
- Director Tregoning Kathleen was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)
- Director Smith Cynthia was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)
- Director Vink Patrick V.J.J. was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)
- Director Thomas Frank E was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)
- Director Jackson Scott Thomas was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)
- Director Pottage John C Jr was granted 10,000 shares, increasing direct ownership by 13% to 85,000 units (SEC Form 4)
- SEC Form 8-K filed by Spero Therapeutics Inc.